<DOC>
	<DOC>NCT00522470</DOC>
	<brief_summary>We aimed to evaluate the effects of rosiglitazone on serum ghrelin and peptide yy levels in diabetic women.</brief_summary>
	<brief_title>Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>newly diagnosed, drug naive women with type 2 diabetes presence of severe cardiovascular disease (eg, New York Heart Association class III or IV congestive heart failure or a history of myocardial infarction or stroke) presence of thyroid, pituitary, nutritional, hepatic, renal, or neoplastic disorders</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>